PT  - JOURNAL ARTICLE
AU  - Shoya Iwanami
AU  - Keisuke Ejima
AU  - Kwang Su Kim
AU  - Koji Noshita
AU  - Yasuhisa Fujita
AU  - Taiga Miyazaki
AU  - Shigeru Kohno
AU  - Yoshitsugu Miyazaki
AU  - Shimpei Morimoto
AU  - Shinji Nakaoka
AU  - Yoshiki Koizumi
AU  - Yusuke Asai
AU  - Kazuyuki Aihara
AU  - Koichi Watashi
AU  - Robin N. Thompson
AU  - Kenji Shibuya
AU  - Katsuhito Fujiu
AU  - Alan S. Perelson
AU  - Shingo Iwami
AU  - Takaji Wakita
TI  - Rethinking antiviral effects for COVID-19 in clinical studies: early initiation is key to successful treatment
AID  - 10.1101/2020.05.30.20118067
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.30.20118067
4099  - http://medrxiv.org/content/early/2020/06/03/2020.05.30.20118067.short
4100  - http://medrxiv.org/content/early/2020/06/03/2020.05.30.20118067.full
AB  - Development of an effective antiviral drug for COVID-19 is a global health priority. Although several candidate drugs have been identified through in vitro and in vivo models, consistent and compelling evidence for effective drugs from clinical studies is limited. The lack of evidence could be in part due to heterogeneity of virus dynamics among patients and late initiation of treatment. We first quantified the heterogeneity of viral dynamics which could be a confounder in compassionate use programs. Second, we demonstrated that an antiviral drug is unlikely to be effective if initiated after a short period following symptom onset. For accurate evaluation of the efficacy of an antiviral drug for COVID-19, antiviral treatment should be initiated before or soon after symptom onset in randomized clinical trials.One Sentence Summary Study design to evaluate antiviral effect.Competing Interest StatementThe authors have declared no competing interest.Funding StatementA Grant-in-Aid for JSPS Research Fellows 19J12319 (to S. Iwanami), Scientific Research (KAKENHI) B 18KT0018 (to S.I.), 18H01139 (to S.I.), 16H04845 (to S.I.), 17H04085 (to K.W.), Scientific Research in Innovative Areas 20H05042 (to S.I.), 19H04839 (to S.I.), 18H05103 (to S.I.); AMED CREST 19gm1310002 (to S.I.); AMED J-PRIDE 19fm0208006s0103 (to S.I.), 19fm0208014h0003 (to S.I.), 19fm0208019h0103 (to S.I.), 19fm0208019j0003 (to K.W.); AMED Research Program on HIV/AIDS 19fk0410023s0101 (to S.I.); Research Program on Emerging and Re-emerging Infectious Diseases 19fk0108050h0003 (to S.I.); Program for Basic and Clinical Research on Hepatitis 19fk0210036h0502 (to S.I.), 19fk0210036j0002 (to K.W.); Program on the Innovative Development and the Application of New Drugs for Hepatitis B 19fk0310114h0103 (to S.I.), 19fk0310114j0003 (to K.W.), 19fk0310101j1003 (to K.W.), 19fk0310103j0203 (to K.W.); JST MIRAI (to S.I. and K.W.); JST CREST (to S.I. and K.W.); Mitsui Life Social Welfare Foundation (to S.I. and K.W.); Shin-Nihon of Advanced Medical Research (to S.I.); Suzuken Memorial Foundation (to S.I.); Life Science Foundation of Japan (to S.I.); SECOM Science and Technology Foundation (to S.I.); The Japan Prize Foundation (to S.I.); Toyota Physical and Chemical Research Institute (to S.I.); The Yasuda Medical Foundation (to K.W.); Smoking Research Foundation (to K.W.); and The Takeda Science Foundation (to K.W.). Los Alamos National Laboratory LDRD Program (to A.S.P.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is a simulation study, which does not require IRB approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data examined in our manuscript were extracted from the published studies of SARS-CoV-2. We do not have the right to publicize the data, but we have cited those papers in the manuscript.